Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson Sells 2,500 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the transaction, the chief financial officer now directly owns 165,110 shares in the company, valued at $18,190,168.70. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Gilead Sciences Trading Down 2.6%

NASDAQ GILD opened at $108.00 on Wednesday. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The company has a 50-day simple moving average of $105.88 and a 200-day simple moving average of $102.49. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The firm has a market capitalization of $134.34 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences’s quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the firm posted ($1.32) EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.93%. Gilead Sciences’s dividend payout ratio is presently 66.53%.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in GILD. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth about $25,000. Activest Wealth Management raised its position in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth about $29,000. Colonial Trust Advisors raised its position in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 216 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective on the stock. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.